A carregar...
The role of brigatinib in crizotinib-resistant non-small cell lung cancer
Despite the advances in new targeted therapies in ALK positive population, most patients progress under ALK inhibitors within first 2 years; being the brain the most frequent site of relapse. ALK mutations, in ~30% of patients, are the main known mechanism of resistance. Classically, second-generati...
Na minha lista:
| Publicado no: | Cancer Manag Res |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5783011/ https://ncbi.nlm.nih.gov/pubmed/29403310 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S129963 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|